Email Alert RSS
Volume 13 Issue 6
Nov.  2022
Turn off MathJax
Article Contents
Abstract
References
HE Liyun, ZHANG Huabing, LI Yuxiu. Comprehensive Assessment and Rational Decision-making: Based on Recent FindingsAbout Safety of Glucagon-like Peptide-1 Receptor Agonists[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 948-952. DOI: 10.12290/xhyxzz.2022-0391
Citation: HE Liyun, ZHANG Huabing, LI Yuxiu. Comprehensive Assessment and Rational Decision-making: Based on Recent FindingsAbout Safety of Glucagon-like Peptide-1 Receptor Agonists[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 948-952. DOI: 10.12290/xhyxzz.2022-0391
shu

Comprehensive Assessment and Rational Decision-making: Based on Recent FindingsAbout Safety of Glucagon-like Peptide-1 Receptor Agonists

  • Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds: 

Beijing Natural Science Foundation M22014

CAMS Innovation Fund for Medical Sciences 2021-1-I2M-002

More Information
  • Corresponding author:

    ZHANG Huabing, E-mail: huabingzhangchn@163.com

  • Received Date: July 13, 2022
  • Accepted Date: August 28, 2022
  • Available Online: September 26, 2022
  • Issue Publish Date: November 29, 2022
    Graphical Abstract
    • Abstract
  • Glucagon-like peptide-1 receptor agonists (GLP-1RAs), as a kind of novel hypoglycemic agent, are widely used in patients with type 2 diabetes. GLP-1RAs are effective in glycemic control with low risk of hypoglycemia, significant weight loss, and cardiovascular benefit and renal protection. The most common adverse effects of GLP-1RAs are mild to moderate gastrointestinal symptoms, which generally resolve over time. The use of GLP-1RAs also increases the risk of gallbladder or biliary diseases, especially when used at higher doses, for longer durations, and for weight loss, but the absolute risk of gallbladder or biliary tract disease is small. Clinicians and patients need to carefully weigh the benefits and risks of GLP-1RAs to make decisions for the rational use of GLP-1RAs.
    • FullText(HTML)
    • References (38)
  • [1]
    Alicic RZ, Cox EJ, Neumiller JJ, et al. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence[J]. Nat Rev Nephrol, 2021, 17: 227-244. DOI: 10.1038/s41581-020-00367-2
    [2]
    Kalyani RR. Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes[J]. N Engl J Med, 2021, 384: 1248-1260. DOI: 10.1056/NEJMcp2000280
    [3]
    Nauck MA, Wefers J, Meier JJ. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes[J]. Lancet Diabetes Endocrinol, 2021, 9: 525-544. DOI: 10.1016/S2213-8587(21)00113-3
    [4]
    Marx N, Davies MJ, Grant PJ, et al. Guideline recommendations and the positioning of newer drugs in type 2 diabetes care[J]. Lancet Diabetes Endocrinol, 2021, 9: 46-52. DOI: 10.1016/S2213-8587(20)30343-0
    [5]
    Kelsey MD, Nelson AJ, Green JB, et al. Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison[J]. J Am Coll Cardiol, 2022, 79: 1849-1857.
    [6]
    Nauck MA, Quast DR, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art[J]. Mol Metab, 2021, 46: 101102. DOI: 10.1016/j.molmet.2020.101102
    [7]
    Ceriello A, Prattichizzo F, Phillip M, et al. Glycaemic management in diabetes: old and new approaches[J]. Lancet Diabetes Endocrinol, 2022, 10: 75-84. DOI: 10.1016/S2213-8587(21)00245-X
    [8]
    Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials[J]. BMJ, 2021, 372: m4573.
    [9]
    Brown E, Heerspink HJL, Cuthbertson DJ, et al. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications[J]. Lancet, 2021, 398: 262-276. DOI: 10.1016/S0140-6736(21)00536-5
    [10]
    Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials[J]. Lancet Diabetes Endocrinol, 2021, 9: 653-662. DOI: 10.1016/S2213-8587(21)00203-5
    [11]
    中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13: 315-409. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK202108007.htm
    [12]
    Li S, Vandvik PO, Lytvyn L, et al. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline[J]. BMJ, 2021, 373: n1091.
    [13]
    Marx N, Grant PJ, Cosentino F. Compelling evidence for SGLT2 inhibitors and GLP-1 receptor agonists as first-line therapy in patients with diabetes at very high/high cardiovascular risk[J]. Eur Heart J, 2020, 41: 329-330. DOI: 10.1093/eurheartj/ehz853
    [14]
    He L, Yang N, Xu L, et al. Subpopulation Differences in the Cardiovascular Efficacy of Long-Acting Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis[J]. Diabetes Ther, 2020, 11: 2121-2143. DOI: 10.1007/s13300-020-00882-2
    [15]
    Lee MMY, Ghouri N, McGuire DK, et al. Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes[J]. Diabetes Care, 2021, 44: 1236-1241. DOI: 10.2337/dc20-3007
    [16]
    Davies MJ, Bergenstal R, Bode B, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial[J]. JAMA, 2015, 314: 687-699. DOI: 10.1001/jama.2015.9676
    [17]
    Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management[J]. N Engl J Med, 2015, 373: 11-22. DOI: 10.1056/NEJMoa1411892
    [18]
    Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity[J]. N Engl J Med, 2021, 384: 989-1002. DOI: 10.1056/NEJMoa2032183
    [19]
    Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: the STEP 4 Randomized Clinical Trial[J]. JAMA, 2021, 325: 1414-1425. DOI: 10.1001/jama.2021.3224
    [20]
    Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: the STEP 3 Randomized Clinical Trial[J]. JAMA, 2021, 325: 1403-1413. DOI: 10.1001/jama.2021.1831
    [21]
    Christensen RM, Juhl CR, Torekov SS. Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists[J]. Drug Saf, 2019, 42: 957-971. DOI: 10.1007/s40264-019-00812-7
    [22]
    US Food, Drugs Administration. FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014[EB/OL]. (2021-06-04)[2022-07-01]. https://www.fda.gov/news-events/press-announcements/fda-appro- ves-new-drug-treatment-chronic-weight-management-first-2014.
    [23]
    Bettge K, Kahle M, Abd El Aziz MS, et al. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials[J]. Diabetes Obes Metab, 2017, 19: 336-347. DOI: 10.1111/dom.12824
    [24]
    Singh S, Chang HY, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study[J]. JAMA Intern Med, 2013, 173: 534-539. DOI: 10.1001/jamainternmed.2013.2720
    [25]
    Douros A, Filion KB, Yin H, et al. Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy[J]. Diabetes Care, 2018, 41: 2330-2338. DOI: 10.2337/dc17-2280
    [26]
    Piccoli GF, Mesquita LA, Stein C, et al. Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis[J]. J Clin Endocrinol Metab, 2021, 106: 912-921. DOI: 10.1210/clinem/dgaa891
    [27]
    Pizzimenti V, Giandalia A, Cucinotta D, et al., Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database[J]. J Clin Pharm Ther, 2016, 41: 116-118. DOI: 10.1111/jcpt.12373
    [28]
    Faillie JL, Yu OH, Yin H, et al. Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus[J]. JAMA Intern Med, 2016, 176: 1474-1481. DOI: 10.1001/jamainternmed.2016.1531
    [29]
    Lundgren JR, Janus C, Jensen SBK, et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined[J]. N Engl J Med, 2021, 384: 1719-1730. DOI: 10.1056/NEJMoa2028198
    [30]
    le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial[J]. Lancet, 2017, 389: 1399-1409. DOI: 10.1016/S0140-6736(17)30069-7
    [31]
    Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes[J]. N Engl J Med, 2016, 375: 1834-1844. DOI: 10.1056/NEJMoa1607141
    [32]
    Nauck MA, Muus Ghorbani ML, Kreiner E, et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial[J]. Diabetes Care, 2019, 42: 1912-1920. DOI: 10.2337/dc19-0415
    [33]
    He L, Zhang H. Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes[J]. N Engl J Med, 2021, 385: 2106-2107.
    [34]
    He L, Wang J, Ping F, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials[J]. JAMA Intern Med, 2022, 182: 513-519. DOI: 10.1001/jamainternmed.2022.0338
    [35]
    Abrahami D, Douros A, Yin H, et al. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study[J]. BMJ, 2018, 363: k4880.
    [36]
    Sugerman HJ, Brewer WH, Shiffman ML, et al. A multicenter, placebo-controlled, randomized, double-blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypass-induced rapid weight loss[J]. Am J Surg, 1995, 169: 91-96; discussion 96-97. DOI: 10.1016/S0002-9610(99)80115-9
    [37]
    Shiffman ML, Kaplan GD, Brinkman-Kaplan V, et al. Prophylaxis against gallstone formation with ursodeoxycholic acid in patients participating in a very-low-calorie diet program[J]. Ann Intern Med, 1995, 122: 899-905. DOI: 10.7326/0003-4819-122-12-199506150-00002
    [38]
    He L, Wang J, Ping F, et al. Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials[J]. BMJ, 2022, 377: e068882.
    • Related Articles

  • Cited by

    Periodical cited type(0)

    Other cited types(1)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (296) PDF downloads (37) Cited by(1)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close